EUVIMEDOpdag EUVIMED
Crossref

Semaglutide reduces drinking in adults with alcohol use disorder and obesity

The Brown University Psychopharmacology Update · 2026-08 · 37 (8) · 1-6

DOI: 10.1002/pu.31472 ↗

At a glance

Journal article in The Brown University Psychopharmacology Update, published online on 2026-06-28.

AbstractBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Weekly doses of semaglutide were more effective than placebo in reducing heavy drinking in patients with alcohol use disorder (AUD) and comorbid obesity, a 26‐week trial has found. Semaglutide also resulted in improvement in several metabolic measures, including weight and body mass index (BMI). Study results were published online May 2, 2026 in The Lancet .

Cite

APA

(2026). Semaglutide reduces drinking in adults with alcohol use disorder and obesity. The Brown University Psychopharmacology Update, 37(8), 1-6. https://doi.org/10.1002/pu.31472

Vancouver

Semaglutide reduces drinking in adults with alcohol use disorder and obesity. The Brown University Psychopharmacology Update. 2026;37(8):1-6. doi:10.1002/pu.31472

BibTeX
@article{euvimed2026,
  title = {Semaglutide reduces drinking in adults with alcohol use disorder and obesity},
  journal = {The Brown University Psychopharmacology Update},
  year = {2026},
  volume = {37},
  number = {8},
  pages = {1--6},
  doi = {10.1002/pu.31472}
}
Start for free →